Navigation Links
Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- Aires Pharmaceuticals, Inc., announced today that it has successfully completed a $20 million Series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund L.P.  Additionally, Aires further bolstered its cash reserves by entering into an agreement with Novartis International Pharmaceutical Limited whereby Novartis has been granted an exclusive option to acquire Aires following the successful completion of a Phase 2 clinical study of Aironite™ to treat pulmonary arterial hypertension.  The agreement also includes a right to an exclusive worldwide license under pre-agreed conditions.  Including the initial acquisition payment plus potential additional regulatory and sales milestone payments, the deal with Novartis could reach $250 million.

The Series B financing includes new investor MPM Capital and the existing investor, ProQuest Investments.  Dr. William Greene, Managing Director of MPM Capital, will join Aires' Board of Directors.

"ProQuest Investments created Aires and has been a dedicated backer of the company since inception.  We are pleased that MPM and ProQuest will support the company, and along with Novartis share our enthusiasm for the potential of Aironite to help patients with pulmonary arterial hypertension," said Wendy Johnson, Founder, President and CEO of Aires.  The current financing will be sufficient to complete the planned clinical development program.

William Greene, M.D., Managing Director at MPM Capital, said, "We at MPM are excited about the potential of Aironite to impact the lives of pulmonary arterial hypertension patients and look forward to working with Aires in developing this novel approach to a devastating disease."

About Aironite™  

Aironite™ is an inhaled nitric oxide prodrug that has been shown in animal models to cause vasodilatation as well as potentially prevent or reverse the pulmonary artery smooth muscle cell proliferation associated with pulmonary arterial hypertension.  Significant preclinical development has been conducted by inventors Dr. Mark Gladwin and colleagues, formerly from the National Heart, Lung and Blood Institute of the NIH.  In early clinical trials conducted by Aires, Aironite administration resulted in nitric oxide production and reduction of pulmonary artery pressure.

About MPM Capital  

MPM Capital is one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2 billion, MPM Capital is uniquely structured to invest globally in healthcare innovation.

About ProQuest Investments

Founded in 1998, ProQuest Investments is a healthcare venture capital firm with over $875 million under management.  With a proven superior track record and over 40 investments the portfolio reflects the rich diversity of the healthcare industry and exemplifies commitment to fostering the growth of exceptional businesses.

About Aires Pharmaceuticals

Aires Pharmaceuticals, Inc., is a privately held drug development company developing Aironite for cardiopulmonary indications such as pulmonary hypertension.  The company is headquartered in San Diego, California.


'/>"/>
SOURCE Aires Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Buenos Aires Welcomes CPhI South America 2010
2. T-System Provides Free Medical Documentation Templates and Bi-Lingual Triage Questionnaires for Haiti Relief Medical Personnel
3. Omthera Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
5. DUSA Pharmaceuticals, Inc.® to Host Third Quarter 2010 Corporate Highlights and Financial Results Conference Call
6. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
7. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
8. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
9. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
10. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
11. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):